Clinical Trials
Explore the key clinical trials that validate the safety, effectiveness, and long-term benefits of GLP-1 receptor agonists, including Mounjaro.
At CutKilo, we base our treatments on robust scientific evidence, ensuring you receive care backed by comprehensive research. Discover the landmark studies shaping modern weight-loss medicine.
SURMOUNT-1 trial
Published 4 June 2022, The New England Journal of Medicine
The Surmount-1 trial was a phase 3 clinical trial of 2,539 participants that evaluated the effectiveness and safety of tirzepatide (Mounjaro) for weight loss in adults with obesity or overweight but without diabetes.
The Surmount-1 trial confirmed that tirzepatide is highly effective for weight loss in people without diabetes, showing greater reductions in body weight compared to other available treatments. This led to its FDA approval for obesity treatment under the brand name Mounjaro.
SURMOUNT-2, SURMOUNT-3 and SURMOUNT-4 trials
Published 19 August 2023, The Lancet
Following Surmount-1, additional trials confirmed tirzepatide’s effectiveness in people with diabetes (Surmount-2), after diet interventions (Surmount-3), and for long-term weight maintenance (Surmount-4).
Surmount-2
In people with type 2 diabetes, tirzepatide led to 15.7% weight loss (15 mg), 13.4% (10 mg), and 9.2% (5 mg) vs. 3.3% with placebo.
SURMOUNT-3
After a 12-week diet phase, tirzepatide delivered an additional 21.1% weight loss (15 mg) vs. 3.3% weight regain with placebo.
SURMOUNT-4
Those who continued tirzepatide maintained a 21.1% total weight reduction, while those switched to placebo experienced some weight regain over time.
A study of 2.4 million participants reveals potential advantages for cardiometabolic & psychiatric conditions
Published 20 January 2025, Nature Medicine
The US Department of Veterans Affairs databases were used to develop a cohort of people with diabetes who initiated GLP-1RA (receptor agonist).
GLP-1RA drugs were associated with significant benefits to neurological and behavioural health, with reduced risks of seizures and addiction to substances such as alcohol, cannabis, stimulants and opioids. People taking the weight-loss drugs also experienced decreased risks of suicidal ideation, self-harm, bulimia and psychotic disorders such as schizophrenia.
GLP-1RA use was associated with a reduced risk of neurocognitive disorders (e.g., dementia and Alzheimer’s disease) and seizures.Furthermore, this drug also exhibited a reduced risk of myocardial infarction, ischemic stroke, and haemorrhagic stroke.
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Published 8 July 2024, JAMA Intermal Medicine
A recent study published in JAMA Internal Medicine compared the effectiveness of semaglutide (Ozempic) and Tirzepatide (Mounjaro) for weight loss in adults with overweight or obesity. The research found that tirzepatide led to greater weight loss than semaglutide. Specifically, a higher proportion of participants on tirzepatide achieved significant weight loss milestones. These findings suggest that tirzepatide may be a more effective option for weight management in individuals with overweight or obesity.
Crunch the numbers with our BMI Calculator
*Enter your height and weight into our BMI calculator to estimate your healthy range and see how much weight you can safely lose. We’ll use this figure as a useful indication in your initial consultation.
If you have an Asian, Chinese, Middle Eastern, Black African or African-Caribbean family background you’ll need to use a lower BMI score to measure overweight and obesity:
- 23 to 27.4 -you’re in the overweight range
- 27.5 or above -you’re in the obese range
